951163-60-3

951163-60-3 structure

Name: 7-[(3S,5S)-3-amino-5-methylpiperidin-1-yl]-1-cyclopropyl-8-methoxy-4-oxoquinoline-3-carboxylic acid,2-hydroxybutanedioic acid
Chemical Name: 7-[(3S,5S)-3-amino-5-methylpiperidin-1-yl]-1-cyclopropyl-8-methoxy-4-oxoquinoline-3-carboxylic acid,2-hydroxybutanedioic acid
CAS Number: 951163-60-3
Molecular Formula: C₂₄H₃₁N₃O₉
Molecular Weight: 505.51800
Catalog: API Synthetic anti-infective drugs Antifungal drugs
Create Date: 2018-12-23 08:50:10
Modify Date: 2024-01-04 10:46:58
Nemonoxacin (TG-873870) malate is a nonfluorinated quinolone antibiotic. Nemonoxacin malate has broad-spectrum activity against Gram-positive, Gram-negative and atypical pathogens. Nemonoxacin malate can inhibit drug-resistant Streptococcus pneumoniae and (HY-121544) Methicillin-resistant Staphylococcus aureus. Nemonoxacin malate can be used for the research of community-acquired pneumonia[1][2].

Name	7-[(3S,5S)-3-amino-5-methylpiperidin-1-yl]-1-cyclopropyl-8-methoxy-4-oxoquinoline-3-carboxylic acid,2-hydroxybutanedioic acid
Synonyms	NEMONOXACIN MALIC ACID 2-HYDROXY-BUTANEDIOIC ACID COMPD. WITH 7-[(3S,5S)-3-AMINO-5-METHYL-PIPERIDIN-1-YL]-1-CYCLOPROPYL-1,4-DIHYDRO-8-METHOXY-4-OXO-3-QUINOLINECARBOXYLIC ACID 7-((3S,5S)-3-amino-5-methylpiperidin-1-yl)-1-cyclopropyl-8-methoxy-4-oxo-1,4-dihydroquinoline-3-carboxylic acid malate

Description	Nemonoxacin (TG-873870) malate is a nonfluorinated quinolone antibiotic. Nemonoxacin malate has broad-spectrum activity against Gram-positive, Gram-negative and atypical pathogens. Nemonoxacin malate can inhibit drug-resistant Streptococcus pneumoniae and (HY-121544) Methicillin-resistant Staphylococcus aureus. Nemonoxacin malate can be used for the research of community-acquired pneumonia[1][2].
Related Catalog	Research Areas >> Infection Signaling Pathways >> Anti-infection >> Bacterial
In Vitro	Nemonoxacin has antibacterial activity against Chlamydia pneumoniae with MIC90s of 0.06 μg/mL[1]. Nemonoxacin has highly active against community-acquired MRSA (CA-MRSA) (MIC90: 0.5 and 0.06 μg/ml), and exerts limited activity against (HY-B0356) Ciprofloxacin-resistant MRSA (MIC90: 1 μg/ml), and (HY-B0671) Vancomycin-intermediate MRSA (MIC90: 2 μg/ml)[2].
References	[1]. Chotikanatis K, et al. In vitro activity of nemonoxacin, a novel nonfluorinated quinolone antibiotic, against Chlamydia trachomatis and Chlamydia pneumoniae. Antimicrob Agents Chemother. 2014;58(3):1800-1. [2]. Lai CC, et al. Nemonoxacin (TG-873870) for treatment of community-acquired pneumonia. Expert Rev Anti Infect Ther. 2014 Apr;12(4):401-17.

378746-64-6

617-48-1

~71%

951163-60-3

Literature: The Procter and Gamble Company Patent: US2007/232804 A1, 2007 ; Location in patent: Page/Page column 9; 10 ;

Precursor 2
378746-64-6 617-48-1
DownStream 0